NascaCell Technologies AG and Boehringer Ingelheim sign collaboration agreement on therapeutic Microbodies™

Boehringer Ingelheim and NascaCell Technologies AG, a Munich-based biotechnology company, have signed a contract under which NascaCell will generate therapeutic Microbodies™ against up to four targets nominated by Boehringer Ingelheim.

NascaCell’s Microbodies™ are extremely stable, small proteins. Due to size and physico-chemical stability they are much more comparable to small molecules than other biological therapeutics. NascaCell’s technology allows the functional transfer of known peptide sequences into these protein scaffolds, which provide protease-resistance and structural constrains. Thereby Microbodies™ open a new route to explore the enormous therapeutic potential of peptides.

NascaCell will receive research support and future product related milestone payments. Further financial details were not disclosed.

”We are very happy to work with Boehringer Ingelheim as one of the leading pharmaceutical companies. Their interest in our Microbodies™ as therapeutic candidates is an external validation of this technology and an important step in our efforts to establish this novel class of biologicals as product candidates for research and therapeutic applications,” said Dr. M. Blind, Chief Scientific Officer at NascaCell.